Chapter 27 Mediators of Ocular Inflammation MATTHEW J. CHAPIN, PAULA J. WUN and MARK B. ABELSON Table Of Contents |
PREFORMED MEDIATORS OXIDATIVE PRODUCTS OF ARACHIDONIC ACID METABOLISM COMPLEMENT CYTOKINES AND LYMPHOKINES ADHESION MOLECULES SUMMARY REFERENCES |
Mediators are biologically active chemical compounds contained within inflammatory
cells. On release from the cell, mediators act in a specific
manner and at a specific site to induce a component of the inflammatory
or immunologic process. Our understanding of the roles individual
mediators play in the inflammatory and allergic disease has increased
rapidly. This understanding allows us to identify rational and more effective
means of therapy. The mast cell is the principal effector cell for allergic reactions in the eye and other organ systems. The mast cell contains more than 30 preformed mediators, and mast cell degranulation stimulates the synthesis of many more. Mediators that are preformed and released by the mast cell, or are synthesized after mast cell activation, will be the primary focus of this review. However, other mediators with a role in ocular inflammation will also be discussed. The mast cell surface has as many as 500,000 immunoglobulin-E (IgE) receptors, 10% of which are occupied in vivo.1 The Fc portion of the IgE molecule, the portion attached to the mast cell membrane, changes as a result of IgE cross-linking with the offending allergen, activating a serine esterase.2 This leads to an intracellular biochemical cascade causing mast cell degranulation and the subsequent release of preformed mediators, including histamine, eosinophil chemotactic factor of anaphylaxis, high-molecular-weight neutrophil chemotactic factor, and platelet-activating factor (Fig. 1). These mediators attract eosinophils and neutrophils, which restore homeostasis to the tissue. The signs and symptoms of an acute allergic reaction result from this intricate network of mediator interaction.
The inflammatory process is regulated internally by a negative feedback system. The interaction of histamine with mast cell surface histamine receptors elevates cyclic adenosine monophosphate (cAMP) concentrations, thereby “turning off” the mast cell.2 The second messengers, cAMP and cyclic guanosine monophosphate (cGMP), further control mediator release from mast cells and basophils.2 Increasing levels of cAMP block mediator release; increasing levels of cGMP stimulate mediator release. Beta-adrenergic receptor activation enhances cAMP levels; alpha-adrenergic receptor activation diminishes cAMP levels. Prostaglandins act by way of adenyl cyclase to increase cAMP levels. Phosphodiesterase degrades cAMP; thus, phosphodiesterase inhibitors can increase cAMP levels. Cholinergic stimulation results in increasing levels of cGMP and mediator release. Thus, allergic symptoms can be treated by increasing cAMP levels or decreasing cGMP levels. Pharmacologic modulation of these feedback mechanisms may provide a novel method for the treatment of allergic diseases. |
PREFORMED MEDIATORS |
HISTAMINE The role of histamine as a mediator of acute inflammation has been clearly established—indeed, histamine represents the prototype of the inflammatory mediators. Histamine is an endogenous substance, widely distributed in mammalian tissue.3 It is stored in the secretory granules of tissue mast cells located primarily in connective tissue associated with blood vessels.4 Histamine is also found in platelets5 and in basophils.6,7 Histamine release can be triggered by both immunologic and nonimmunologic means. Re-exposure of sensitized individuals to an inciting antigen activates cell-bound IgE dimers, inducing mast cell and basophil degranulation and resulting in histamine release. Nonimmunologic mediator release can be induced by agents such as compound 48/80, dextran, and anaphylatoxins (e.g., C3a and C5a), or by trauma.8 Studies in a variety of immediate hypersensitivity models have shown that the release of immediate hypersensitivity mediators is both selective and noncytolytic. Topical application of compound 48/80 produces the signs and symptoms of ocular allergy (itching, vasodilation, chemosis, and mucous discharge) in the eyes of guinea pigs, rabbits, and humans, and serves as a useful tool in screening anti-inflammatory agents.9 The degranulation of human conjunctival mast cells in response to topically applied compound 48/80, as demonstrated by light microscopy, has been confirmed by transmission electron microscopy.10 Mast cell granules enlarge in response to stimulation by compound 48/80; the number of enlarged granules corresponds to the extent of degranulation. Only cells with pink granules (by alkaline Giemsa stain) and granules enlarged to more than 1 μm showed definite evidence of exocytosis. Caulfield and colleagues, using an in vitro human anti-IgE model, have shown that granules enlarge, coalesce, become amorphous, and then discharge within 1 minute of stimulation.11 Only amorphous granules are capable of discharging their contents.11 Dale and Laidlaw12 used animal models to establish that injection of histamine results in collapsed arterial pressure, hypovolemia, and decreased body temperature. These symptoms are characteristic of traumatic or anaphylactic shock. Local application of histamine to skin results in redness, swelling, and flare from the local axon reflex,13 as well as itching from the stimulation of cutaneous nerve endings.14 To date, three different histamine receptor subtypes have been identified: H1, H2, and H3. Both H1 and H2 receptors have been identified in ocular tissue. When injected intradermally, histamine causes a localized triple response. First is the development of erythema immediately surrounding the injection site. Erythema results from vasodilation mediated by both H1 and H2 receptors.15,16 Second to develop is the cutaneous flare that occurs as an indirect response to stimulation of histamine receptors on afferent nonmyelinated nerve endings. Antidromic nerve conduction (the conduction of impulses in a direction opposite to the normal direction) initiates a reflex arc resulting in the release of various neuropeptides, including substance P and calcitonin gene-related peptide. These neuropeptides have a direct effect on arteriolar vasodilation.17 Finally, wheal results from the exudation of plasma through gaps between the vascular endothelium of postcapillary venules. This is mediated by H1 receptors.18 In addition to the triple response, intradermal injection of histamine causes the sensory response of itching.19 Topical application of histamine to the rabbit or human eye produces the signs and symptoms of an allergic reaction (itching, redness, and swelling) in a dose-dependent fashion.20 H1 receptor activation results in itching21 and redness,20 whereas H2 receptor activation leads to redness.22 The presence of a dual receptor system similar to that of skin has been demonstrated in the eye (Fig. 2). The highly selective H2 receptor agonist dimethylaminopropylisothiourea (dimaprit) produces diffuse vasodilation that can be blocked by cimetidine, an H2 antagonist, but not by antazoline, an H1 antagonist.22 Stimulation of the H1 receptor with the H1 agonist 2-(2-amino-ethyl)thiozole dihydrochloride produces itch and minimal vasodilation, which can be prevented by pheniramine maleate, an H1 antagonist, but not by cimetidine.21 Histamine levels have been described in normal human tears (5 to 10 ng/ml). In the past, these levels were not found to be consistently elevated in patients with allergic conjunctivitis, but only in the tears of patients with active vernal keratoconjunctivitis (VKC; 16 ng/ml).23,24 This elevation is probably the result of the extensive mast cell degranulation demonstrated in patients with VKC by light and electron microscopy.25 In addition, patients with VKC have four times as many mast cells in their conjunctiva as normal individuals,25 and the location of these mast cells is more superficial than in the normal conjunctiva.26 Such patients are, therefore, at greater risk for antigenic attack. A 1990 study examined the presence of histaminase activity in human tears after in vivo conjunctival antigen challenge.27 Inactivation of histaminase resulted in a 15-fold elevation of histamine recovery. Enzyme-inactivated samples had histamine levels of 107.26 ng/ml, whereas untreated samples had histamine levels of 7.07 ng/ml. These results demonstrate the presence of histaminase activity in human tears and suggest that histaminase activity may have confounded the identification of histamine in ocular allergic disorders other than VKC. A 1995 study showed that the degradation of histamine was significantly lower in patients with VKC than controls in both tears and plasma.28 TRYPTASE Tryptase is a preformed, tetrameric, serine endoprotease found in mast cells. It is stored in abundant quantities in its fully active form. Because tryptase is unique to mast cells, it is an excellent marker for them.29,30 Elevated levels of tryptase have been found in tears of patients after eye-rubbing. In addition, allergen challenge or provocation with compound 48/8031,32 also results in increased levels of tryptase in tears. Tryptase levels appear elevated during the early-phase reaction, but not during the late-phase reaction, after ocular allergen challenge.33 Tryptase is found elevated in patients with VKC, even during the remission phase.32,34 In addition to the eye, tryptase has been found in other biologic fluids such as serum,35 bronchial lavage fluid,36 nasal lavage secretions,37 skin,38 synovial fluid,39 and blisters.40 Tryptase has the ability to potentiate the effect of histamine, activate eosinophils and mast cells, and attract eosinophils and neutrophils. Because of these actions, tryptase inhibitors are being evaluated as potential therapies for asthma and have been shown to have effective anti-inflammatory properties. Mast cell stabilizers have been shown to reduce tryptase levels after allergen challenge.33 Tryptase also has the ability to degrade neuropeptides such as vasoactive intestinal peptide (VIP), peptide histidine-methionine, and calcitonin gene-related peptide. VIP is a prominent bronchodilator, and it is postulated that the destruction of VIP by tryptase results in the increased bronchomotor tone and bronchial hyperresponsiveness41 of asthma. The exact role of tryptase in ocular inflammation is not yet fully understood. CHYMASE Two mast cell subtypes have been described: T mast cells, which contain tryptase, and TC mast cells, which contain tryptase and chymase.29 Chymase is a serine endoprotease that is stored, preformed and fully active, in the TC mast cells. Unlike tryptase, chymase is inhibited by plasma proteinase inhibitors.42 The presence of chymase has not yet been demonstrated in the eye, although its presence is suggested by the large number of conjunctival mast cells of the MCtc phenotype. HEPARIN Heparin forms complexes with proteases and is released on degranulation of mast cells. Heparin has been shown to have anti-inflammatory properties43 and has been used for the treatment of allergic contact dermatitis,44 but there are only preliminary reports on the use of heparin in ocular allergy.45 Heparin may serve as an endogenous mediator that provides negative feedback on the release of proinflammatory mediators from the mast cell. EOSINOPHIL CHEMOTACTIC FACTOR OF ANAPHYLAXIS Eosinophil chemotactic factor of anaphylaxis (ECFA), a preformed mediator of immediate hypersensitivity, was first found in diffusates of guinea pig lung46 and human lung.47 It was subsequently extracted from rat mast cells,48 human leukemic basophils,7 human mast cell-rich lung,48 and nasal polyps.49 The activity of ECFA resides in two closely related tetrapeptides.50 ECFA is released during repeated mast cell challenge and degranulation in severe ocular allergic disease. ECFA is a potent chemotactic factor for eosinophils; therefore, the release of large amounts of ECFA is responsible for conjunctival eosinophilia.51 The presence of eosinophils in a conjunctival scraping is always indicative of ocular allergy. In fact, a conjunctival scraping containing two or more eosinophils per high-power field is considered diagnostic of ocular allergy.51 However, by definition, eosinophils do not have to be present in conjunctival scrapings to make the clinical diagnosis of ocular allergic disease, because they may be located only deep in conjunctival tissues. ECFA is more selective than complementderived fragments,52 cocytotoxin,53 and peptides extracted from neoplasms.54 Interaction with ECFA reduces the chemotactic responsiveness of eosinophils,55 thereby retaining these cells at a specific site for regulatory purposes. Eosinophils release a number of substances that modulate the mast cell response and limit mediator activity: histaminase inactivates histamine,56–58 phospholipase inactivates platelet-activating factor,59 and aryl sulfatase inactivates leukotrienes.60–62 EOSINOPHIL GRANULE MAJOR BASIC PROTEIN In addition to their beneficial role as modulators of inflammation, eosinophils are also responsible for tissue destruction, as noted in the cytotoxic effects of certain granular proteins on parasites and mammalian tissues.63 Eosinophil granule major basic protein (EMBP) accounts for more than 50% of the eosinophil granule protein and 25% of the total cellular protein.64,65 EMBP is a strongly cationic molecule with a molecular weight of 9,300 in humans and 11,000 in guinea pigs.66,67 A harmful role has been suggested for the eosinophil because of the markedly increased levels of EMBP is asthmatic sputum,68 and the ability of EMBP to mimic the pathologic changes seen in asthma.69 It has been demonstrated to elicit mast cell70 and basophil71 degranulation. Both VKC and contact lens-associated giant papillary conjunctivitis are associated with marked mast cell degranulation and eosinophil infiltration,72,73 providing further evidence that eosinophils play a role in tissue damage. Increased tear levels of both EMBP and Charcot-Leyden crystal protein have been detected in patients with VKC. The increased EMBP levels appear to correspond to the severity of the disease.74 Also, immunofluorescence of conjunctival tissue from normal patients revealed little or no EMBP, whereas specimens from patients with VKC and contact lens-associated giant papillary conjunctivitis revealed significant EMBP deposition.75 However, in this study no correlation between the intensity of EMBP deposition and the severity of disease was documented. Thus, it appears that both VKC and contact lens-associated giant papillary conjunctivitis are characterized by eosinophil degranulation with the release of EMBP and other cytotoxic granule proteins that may further stimulate mast cell degranulation.75 The release of EMBP, a powerful epithelial toxic compound, may account for keratitis and shield ulcers in VKC. EMBP deposits were identified by immunofluorescence in the base and the mucus plug in two corneal shield ulcers removed by superficial keratotomy from two patients with VKC. EMBP may also contribute to sustained mast cell degranulation and thus the severe and protracted process associated with this condition.76 PLATELET-ACTIVATING FACTOR Benveniste and colleagues named and characterized platelet-activating factor (PAF) as a phospholipase A2 (PLA2)-sensitive phospholipid,77–80 identified as 1-alkyl-2(R)-acetyl-glycero-3-phosphorylcholine.80,81 PAF is the most potent eosinophil chemotactic factor known and is approximately 100 times more effective than ECFA or leukotriene B4 (LTB4). It has been reported to mediate inflammation and vascular permeability.82 PAF has also been implicated in other pathophysiologic processes,83 such as aggregating platelets, chemotaxis and degradation of eosinophils and neutrophils, bronchoconstriction, increased bronchial responsiveness, and hypotension. Rabbit basophils have been shown to release PAF by an IgE-dependent process.84 Mast cells, eosinophils, monocytes, basophils, polymorphonuclear leukocytes, and macrophages have also been demonstrated to release PAF when stimulated with IgE, a calcium ionophore, or zymosan particles.84 Studies are available on the role of PAF as a mediator of ocular vascular permeability and ocular inflammation.84 Intravenous injection of PAF-acether in rabbits resulted in increased microvascular permeability of the retina characterized by intense ischemia and marked plasma leakage.85 The role of PAF as a chemical mediator in external ocular inflammation was examined in a dose-response study that involved topical application of PAF to rabbit and human eyes.86 Significant hyperemia and chemosis, very similar to the clinical picture of allergic conjunctivitis, were noted. Histologically, PAF was found to be chemotactic for conjunctival neutrophils and eosinophils, and it produced dramatic intravascular margination in the conjunctiva. |
OXIDATIVE PRODUCTS OF ARACHIDONIC ACID METABOLISM |
Calcium-requiring PLA2 and phospholipase C are rapidly activated during an allergic reaction, releasing
cholesteryl esters. Cell membrane phospholipids are metabolized
by the cholesteryl ester, leading to the production of arachidonic
acid. Arachidonic acid is metabolized by two major pathways (the cyclooxygenase
pathway and the lipoxygenase pathway), and the resulting metabolites
are active inflammatory mediators. Topical application of arachidonic
acid, at a concentration low enough to avoid cellular infiltration, iritis, or
elevated intraocular pressure, produced marked chemosis, lid
closure, and mild conjunctival vasodilation and mucous discharge
in a rabbit model.87 Selective inhibition of the cyclooxygenase pathway with aspirin, indomethacin, and
piroxicam significantly blocked both lid closure and chemosis, whereas
pretreatment with the lipoxygenase blocker BW755C produced
only minimal inhibition. Thus, cyclooxygenase seems to be the predominant
pathway of arachidonic acid metabolism in the normal rabbit conjunctiva. The addition of aspirin to the treatment regimen of patients with intractable VKC has produced dramatic improvement in conjunctival and episcleral redness, and resolution of keratitis and limbal infiltration, indicating that many of the signs and symptoms of VKC may be linked to products of the cyclooxygenase pathway.88 CYCLOOXYGENASE PRODUCTS The cyclooxygenase pathway leads to the production of prostaglandins and thromboxanes (Fig. 3). Some of the effects attributed to these products are bronchospasm, coronary and pulmonary vasoconstriction, neutrophil chemoattraction, and augmentation of basophil histamine release (PGF2α, PGD2),89,90 pulmonary vasodilation and inhibition of platelet aggregation (PGI2),91 inhibition of macrophage spreading and surface adherence,92 and bronchodilation93 (PGE2). PGE1 and PGE2 produce vasodilation94 and erythema.95 Prostaglandins can also potentiate edema, enhance pain and fever caused by inflammatory stimuli, and sensitize nerve endings to other agents that induce pain.96 The prostaglandins PGE1, PGE2, PGF2α, and PGD2 have all been isolated from ocular tissue and aqueous humor,97 but PGD2 is the main prostaglandin produced by human mast cells in vitro98,99 and in vivo.100,101 After topical application to guinea pig or human eyes, PGD2 results in redness, conjunctival chemosis, tenacious mucous discharge, and eosinophilic infiltrate.102 Similar signs are seen in patients with ocular allergic disorders. PGE2 has been shown to increase blood flow independently and to synergize with histamine, bradykinin, and interleukin (IL)-1 to increase vascular permeability.103 Some evidence suggests that PGF may also be involved in allergic disease. Elevated tear levels of PGF have been detected in patients with VKC.104 Studies suggest that certain prostaglandins may also have anti-inflammatory actions. Thus, prostaglandins may also play a role in the negative feedback system that defines the allergic response as self-limiting.105 There are other products of the cyclooxygenase pathway: thromboxane (TXA2) and hydroxyheptadecatrienoic acid. TXA2 is a potent vasoconstrictor,106 platelet aggregator,107 and bronchoconstrictor.108 These actions suggest that TXA2 plays a role in bronchial asthma. The role of TXA2 in ocular allergy is unclear. Hydroxyheptadecatrienoic acid serves as a chemotactic factor for human granulocytes.109 LIPOXYGENASE PRODUCTS Nonsteroidal anti-inflammatory agents such as aspirin and indomethacin block the cyclooxygenase pathway, but they do not inhibit the production of the lipoxygenase products of arachidonic acid. Steroids prevent the release of arachidonic acid from membrane phospholipids, perhaps by the formation of peptide inhibitors of phospholipase A2, thus blocking both the cyclooxygenase and lipoxygenase pathways. Therefore, steroids have the ability to block the production not only of prostaglandins and thromboxanes, but also of leukotrienes.110,111 Leukotrienes are products of arachidonic acid metabolism by the lipoxygenase pathway. The initial product 5-hydroperoxyeicosatetraenoic acid (5-HPETE, LTA4) can be converted to 5-hydroxy HETE, 5,12-d1-hydroxy HETE (LTB4), or the sulfidopeptide leukotrienes LTC4, LTD4, and LTE4. LTC4, LTD4, and LTE4 have been identified in tears after allergen challenge (Fig. 4).112 Like LTB4, the cysteine-containing leukotrienes LTC4, LTD4, and LTE4 exert proinflammatory effects. They are potent bronchoconstrictors and are capable of increasing the vascular permeability of postcapillary venules and stimulating mucus secretion in the lung, and thus are implicated in asthma. LEUKOTRIENE LTB4 Probably the most studied leukotriene involved in ocular inflammation, LTB4 is produced predominantly by eosinophils and basophils but also by neutrophils, macrophages, and monocytes. LTB4 has been identified by gas chromatography—mass spectrometry113 as the lipoxygenase product responsible for the transient aggregation of human polymorphonuclear leukocytes induced by arachidonic acid in vitro.114,115 Thus, LTB4 acts as a potent neutrophil chemotactic agent and has platelet-aggregating activity in vitro. In addition, LTB4 exhibits both leukocyte chemokinesis and chemotaxis. In fact, LTB4 appears to be the most potent arachidonic acid metabolite derived by way of initial lipoxygenation, with respect to the in vitro effects on leukocyte aggregation and motility.116 Substantial in vivo data support the chemotactic activity of LTB4 in humans and other animals. These data include evidence of the accumulation of leukocytes at local sites of leukotriene administration (e.g., guinea pig peritoneum,117 rabbit aqueous humor,118 rabbit conjunctiva,119 and human skin120,121), direct observations on preparations (e.g., hamster cheek pouch122 and rabbit mesentery120), the production of neutropenia after intravenous injection in the rabbit,120 and increased plasma exudation in the presence of a vasodilator.123 LTB4 has been found in ocular tissue in rabbits and primates,124 as well as in tears after conjunctival allergen challenge. Topical application of LTB4 has been shown to cause both eosinophil and neutrophil chemotaxis in guinea pig and rat, although eosinophil chemotaxis predominated.125,126 When applied topically to guinea pig conjunctiva, LTB4 resulted in eosinophil chemotaxis.125 In humans, a subcutaneous injection of LTB4 causes a wheal and flare response, followed 2 to 3 hours later by a tender, indurated lesion consisting of a dermal infiltrate of mainly neutrophils. Conjunctival smears from patients with chronic VKC have shown that LTB4 and other leukotrienes are present,127 although their role in allergic conjunctivitis is probably limited. A study on the topical application of LTB4 on hamster conjunctiva did not demonstrate a change in the conjunctival vascular permeability.128 Application of LTB4 topically to human conjunctiva did not produce vasodilation, but biopsy revealed polymorphonuclear leukocyte infiltrates, and the subject reported migraine headaches lasting for more than 2 weeks (unpublished observation). Both PGE2 and PGD2 act synergistically with LTB4 to enhance vascular permeability, resulting in edema formation, subsequent neutrophil infiltration, and also mast cell degranulation. The interactive effects of the products of arachidonic acid metabolism may have clinical significance in that the inhibition of the cyclooxygenase pathway by nonsteroidal anti-inflammatory agents could be beneficial or detrimental, depending on the altered profile of the arachidonic acid metabolites. LTC4, LTD4, AND LTE4 The cysteine-containing leukotrienes, LTC4, LTD4, and LTE4, are potent bronchoconstrictors of peripheral airways in humans and other animals.129–133 Anaphylactic constriction of bronchi from atopic patients sensitive to birch pollen was inhibited by benoxaprofen and a prostacyclin derivative (U-60257), two lipoxygenase blockers. Mepyramine, an antihistamine, and indomethacin, a cyclooxygenase blocker, did not inhibit anaphylactic bronchoconstriction in these patients.134 LTD4 also causes smooth muscle contraction and increases vascular permeability. LTC4 and LTD4 are powerful depressants of myocardial contractile force, with marked negative inotropic effects evident when they are administered in the picogram and nanogram range.135,136 Both LTC4 and histamine increase tracheal insufflation pressure in anesthetized and artificially ventilated guinea pigs, but LTC4 is at least 100 times more potent than histamine and causes a longer-lasting increase.131,137 LTC4 and LTD4 induce mucus secretion in the submucosal glands of dog tracheas.138 These studies implicate these leukotrienes as major mediators of anaphylaxis in the lung. LTE4 has several systemic effects, including vasodilation and potentiating increased vascular permeability produced by histamine and bradykinin. LTD4 has been implicated in seasonal allergic rhinitis, and an LTD4 antagonist has been shown to reduce nasal symptoms in a seasonal allergic rhinitis study.139 However, another rhinitis study followed the rise and fall of inflammatory mediators during a nasal allergen challenge and found no link between clinical symptoms, drug efficacy, and the release of LTC4.140 These contradictory data demonstrate that the role of leukotrienes in ocular allergy, and the potential use of their antagonists as therapies, requires further study. Lipoxygenase products have been identified in tears after allergen challenge,141 but topical application of LTC4 elicited no observable effect in rabbits or humans.142 This is in contrast to other mediators (e.g., LTB4 and PGD2), which are known to contribute to immediate hypersensitivity. These findings suggest that leukotrienes have little role in ocular allergies, although they may play a role in potentiating inflammatory mechanisms that have already started. Much research is needed to determine the role of LTC4, LTD4, and LTE4 in ocular immediate hypersensitivity. HPETE AND HETE In addition to leukotrienes, the lipoxygenase arm of arachidonic acid metabolism also produces HPETE and HETE.143 A study involving a hypoxia model of inflammation detected HETE in the cornea.144 Topical ocular application of HPETE and HETE to rabbit and human eyes had no visible effect on the conjunctiva (unpublished data). HPETE and HETE are known to be potent mucus-stimulating mediators in the lung,145 and it is possible that such a role may exist in the eye. The role of HPETE and HETE in ocular inflammatory conditions remains undefined; however, two HETE subtypes (HETE 1 and HETE 2) have been identified in tears of patients with VKC, pemphigoid, and rosacea.146 |
COMPLEMENT |
Mast cells also participate in nonallergic inflammatory reactions, and
type II hypersensitivity reactions provide an example of this. Type II
hypersensitivity reactions require the participation of complement-fixing
antibodies (IgG1, IgG3, or IgM) and complement. The antibodies are directed against antigens
on the surface of specific cells. Thus, the damage caused by type II hypersensitivity
reactions, and in turn by the complement system, is localized
to a particular target cell or tissue. The mediators in type II
hypersensitivity reactions include complement as well as macrophages
and other leukocytes that liberate their enzymes. The complement system consists of two major divisions: the classical pathway and the alternative pathway.147 Activation begins with the formation of antigen-antibody complexes and the subsequent generation of peptides that lead to a cascade of proteolytic events. IgG and IgM activate the classical pathway via C1.148 Thereafter, the sequential activation of C4, C2, C3, C5, C6, C7, C8, and C9 occurs. In the alternative pathway, IgA, IgE, IgG, endotoxin, zymosan, or other complex polysaccharides from microbial cell walls149 activate C3 and continue on as in the classical pathway. Cleavage of C3 causes the release of histamine from mast cells, neutrophil enzyme release, smooth muscle contraction, suppressor T-cell induction, macrophage IL-1, prostaglandin, and leukotriene secretion,150 and increased vascular permeability. C5 also produces mast cell activation and upregulation of LTB4, ECF, and other arachidonic acid metabolites. Of the other numerous products, C5, C6, and C7 are chemotactic factors, and C8 and C9 lead to cell lysis.151 Thus, the final step to both pathways is membrane damage leading to cell lysis. Complement-mediated cell lysis is also the result of type III hypersensitivity reactions, although ocular manifestations are known to be associated only with systemic type III hypersensitivity diseases. Although no ocular disease has been proven to be a type II hypersensitivity reaction, cicatricial pemphigoid is a candidate.152 Further, C1, C3, factor B, C4, C5, and C9 have been detected in tears153 and normal human corneas.154 Tear levels of C3 have been found to be higher in patients with allergic conjunctivitis. C3 has also been shown to be produced locally by conjunctival tissues in VKC and contact lens-associated giant papillary conjunctivitis.155 Thus, the complement system may play a role in ocular inflammation not related to systemic hypersensitivity reactions. |
CYTOKINES AND LYMPHOKINES |
Macrophages and T lymphocytes secrete lymphokines (e.g., IL-2) and cytokines (e.g., IL-1) and tumor necrosis factor. Lymphokines and cytokines are important
in the inflammatory process by virtue of their powerful ability to
induce specific actions on cells and to serve as chemoattractants. Interleukins
represent another link in the redundancy of the inflammatory
process. Interleukins are not technically mediators, because they are
produced by lymphocytes. However, they are mentioned here to show how
the mast cell is controlled by other cell lines. IL-3 is classified
as a lymphokine and is produced by immunologically stimulated lymphocytes. Excessive
production of this agent resulting from an imbalance between
helper and suppressor T lymphocytes may be one of the basic defects
leading to the allergic diathesis. IL-3 was first defined as a lymphokine capable of inducing the T cell-associated enzyme 20 α-hydroxysteroid dehydrogenase (20αSDH) in cultures of splenic lymphocytes from nu/nu mice.156 Based on the association of 20αSDH primarily with T lymphocytes, it has been suggested that IL-3 may promote the differentiation of early T-cell precursors.157 Further, long-term cultures of splenic lymphocytes have shown that IL-3 supports the growth of a cell type resembling basophils or mast cells.156 Tremendous emphasis has been placed on identifying the role of interleukins in allergy and inflammation, but the research thus far has focused primarily on asthma. In brief, when the T-lymphocyte helper 2 cell (TH2) is activated by antigen, IL-3 and IL-5 are secreted, which in turn activate and recruit eosinophils; IL-4, also secreted by TH2 cells, activates B lymphocytes. Mast cells also release IL-5, which in turn activates eosinophils. IL-4 and IL-5 inhibitors are being studied as potential therapies for asthmatics. There are also interleukins that form a negative feedback loop on the proinflammatory interleukins. IL-12 and gamma interferon both are natural inhibitors of IL-4 and TH2 cell differentiation, and they modulate the inflammatory process. A recent study examined the role of IL-12 in a murine model of allergic conjunctivitis. The authors found that treatment with recombinant IL-12 increases cellular infiltration in the conjunctiva. However, treatment with high levels of IL-12 decreases cellular infiltration in the late phase reaction. In addition, after ocular challenge with allergen, both IL-12 knockout mice and mice pretreated with anti-IL-12 developed a moderate hypersensitivity reaction, but had minimal cellular infiltration. After allergen challenge in gamma interferon knockout mice, the immediate reaction and presence of eosinophils was enhanced.156a This series of experiments demonstrates the importance of IL-12 and interferon gamma in the regulation of ocular allergies and the possibility of their being targets for future therapy. |
ADHESION MOLECULES |
Adhesion molecules represent another class of proteins that play a role
in the inflammatory process, although, like interleukins, they are not
true mediators. Adhesion molecules are membrane-bound proteins that
allow cells to interact with one another. Tumor necrosis factor, interleukins, antigen, histamine, leukotrienes, peroxide, and interferon may
all serve as stimuli for adhesion molecules.158 There are several groups of adhesion molecules. The integrins include intracellular adhesion molecule-1 (ICAM-1). ICAM-1 is normally expressed on endothelium but can be induced on other tissues by cytokines. Although ICAM-1 is not found in normal eyes, expression was noted on conjunctival epithelium after antigen challenge.159 ICAM-1 has been used as a marker for immunotherapy efficacy in allergic rhinitis, and it may serve as a marker for inflammation.158 ICAM-1 may play a significant role in early- and late-phase cellular influx in allergic rhinitis. Many of the new antihistamines have been shown to reduce ICAM-1 in both eye and nasal allergy models.160,161 Selectins are another group of adhesion molecules. Elevated levels of selectins have been identified as contributing to cellular infiltrates in uveitis.162 In another study, patients with VKC were found to have significantly more ICAM-3 and vascular cell adhesion molecule-1 than controls, and endothelial leukocyte adhesion molecule-1 was noted on the vascular endothelial cells. Increased expression of adhesion molecules may play an important role in the pathogenesis of VKC.163 Chemokines are small proteins that combine with G protein-coupled receptors expressed on certain leukocytes. Chemokines are secreted by endothelial cells and leukocytes and function to convert selectins into integrins, which leads to extravasation of cells into the tissues. Eotaxin, monocyte chemotactic protein-3, and “regulated on activation, normal T-cell expressed and secreted” (RANTES) are key types of chemokines that are released by airway epithelium and skin keratinocytes. Elevated monocyte chemotactic protein levels have been found in the cornea in cases of herpetic keratitis.164 One study found monocyte chemotactic protein and RANTES in corneal keratocytes but not corneal epithelium,165 suggesting that the corneal stroma may be important in cell-mediated immunity. Another study found that human conjunctival epithelial cells were capable of producing RANTES in response to inflammatory stimuli, suggesting that RANTES may play a role in recruiting inflammatory cells such as eosinophils and T lymphocytes toward the ocular surface.166 |
SUMMARY |
The components of inflammation are very complex and there appears to be much redundancy in the system, make it difficult to target inflammation in general. Taking advantage of endogenous negative feedback systems may be an opportunity for potential therapy. Further, studies of inflammation in systemic diseases, such as rhinitis and asthma, may provide direction for research in ocular inflammation. As the roles of more inflammatory mediators and their interactions are elucidated, more selective therapeutic approaches directed at the underlying disease process will undoubtedly emerge. |